芬兰 - 芬兰文 - Fimea (Suomen lääkevirasto)

apotex nederland bv - mirtazapinum - tabletti, kalvopäällysteinen - 45 mg - mirtatsapiini

欧盟 - 芬兰文 - EMA (European Medicines Agency)

roche registration gmbh - metoksipolyetyleeniglykoliepoetiini beeta - anemia; kidney failure, chronic - antianemiset valmisteet - treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adult patients (see section 5. treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in paediatric patients from 3 months to less than 18 years of age who are converting from another erythropoiesis stimulating agent (esa) after their haemoglobin level was stabilised with the previous esa (see section 5.

欧盟 - 芬兰文 - EMA (European Medicines Agency)

viatris limited - klopidogreelibesilata - peripheral vascular diseases; stroke; myocardial infarction - antitromboottiset aineet - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st-segmentin nousua akuutti sydäninfarkti, yhdessä asa lääketieteellisesti hoitoa saaneilla potilailla oikeutettu liuotushoito. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. lisätietoja, katso kohta 5.

芬兰 - 芬兰文 - Fimea (Suomen lääkevirasto)

gp-pharm s.a. gp-pharm s.a. - leuprorelini acetas - injektiokuiva-aine ja liuotin, depotsuspensiota varten - 22.5 mg - leuproreliini

芬兰 - 芬兰文 - Fimea (Suomen lääkevirasto)

gp-pharm s.a. gp-pharm s.a. - leuprorelini acetas - injektiokuiva-aine ja liuotin, depotsuspensiota varten - 3.75 mg - leuproreliini

芬兰 - 芬兰文 - Fimea (Suomen lääkevirasto)

pfizer oy - hydrocortisone, oxytetracycline hydrochloride - voide - hydrokortisoni ja antibiootit

芬兰 - 芬兰文 - Fimea (Suomen lääkevirasto)

pfizer oy - hydrocortisone acetate, oxytetracycline hydrochloride, polymyxin b sulfate - korva-/silmätipat, suspensio - hydrokortisoni ja mikrobilääkkeet

芬兰 - 芬兰文 - Fimea (Suomen lääkevirasto)

pfizer oy - hydrocortisone acetate, oxytetracycline hydrochloride, polymyxin b sulfate - korva-/silmävoide - hydrokortisoni ja mikrobilääkkeet

芬兰 - 芬兰文 - Fimea (Suomen lääkevirasto)

b. braun melsungen ag - water for injection - infuusioneste, liuos - liuottimet ja laimentimet

芬兰 - 芬兰文 - Fimea (Suomen lääkevirasto)

b. braun melsungen ag - water for injection - liuotin parenteraaliseen käyttöön - liuottimet ja laimentimet